Verastem, Inc. (NASDAQ:VSTM) has earned a consensus rating of “Buy” from the seven research firms that are currently covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $4.75.
VSTM has been the subject of a number of analyst reports. Zacks Investment Research raised shares of Verastem from a “sell” rating to a “hold” rating in a report on Thursday, May 25th. Cantor Fitzgerald reissued a “hold” rating and issued a $2.00 price objective on shares of Verastem in a report on Thursday, June 8th. Oppenheimer Holdings, Inc. set a $6.00 price objective on shares of Verastem and gave the company a “buy” rating in a report on Sunday, June 4th. Cann reaffirmed a “buy” rating and set a $2.00 target price on shares of Verastem in a research note on Thursday, May 11th. Finally, Jefferies Group LLC reaffirmed a “hold” rating and set a $1.50 target price on shares of Verastem in a research note on Wednesday, June 28th.
Verastem (VSTM) opened at 3.01 on Tuesday. Verastem has a 52 week low of $1.05 and a 52 week high of $4.67. The firm has a 50 day moving average of $3.31 and a 200-day moving average of $2.15. The stock’s market capitalization is $111.35 million.
Verastem (NASDAQ:VSTM) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.34) by $0.02. On average, equities analysts predict that Verastem will post ($1.38) EPS for the current year.
In other Verastem news, Director Timothy J. Barberich purchased 30,000 shares of Verastem stock in a transaction dated Monday, May 15th. The shares were acquired at an average price of $2.45 per share, with a total value of $73,500.00. Following the completion of the transaction, the director now owns 69,462 shares of the company’s stock, valued at $170,181.90. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 12.00% of the company’s stock.
Hedge funds have recently modified their holdings of the company. Alpine Woods Capital Investors LLC acquired a new stake in shares of Verastem during the second quarter valued at about $109,000. TFS Capital LLC acquired a new stake in shares of Verastem during the first quarter valued at about $113,000. Northern Trust Corp boosted its stake in shares of Verastem by 40.3% in the second quarter. Northern Trust Corp now owns 73,750 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 21,178 shares in the last quarter. OxFORD Asset Management LLP acquired a new stake in shares of Verastem during the second quarter valued at about $234,000. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Verastem by 697.6% in the second quarter. Dimensional Fund Advisors LP now owns 289,828 shares of the biopharmaceutical company’s stock valued at $632,000 after buying an additional 253,492 shares in the last quarter. 22.31% of the stock is currently owned by institutional investors and hedge funds.
Verastem Company Profile
Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.
What are top analysts saying about Verastem Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Verastem Inc. and related companies.